54 related articles for article (PubMed ID: 17196704)
1. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Manegold C; Lahm H
Lung Cancer; 2007 Apr; 56(1):115-23. PubMed ID: 17196704
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
[TBL] [Abstract][Full Text] [Related]
3. Association of promoter methylation of
Din Shah NU; Ali MN; Ganai BA; Mudassar S; Khan MS; Kour J; Waza AA; Rasool MT; Lone AM
Heliyon; 2020 Feb; 6(2):e03488. PubMed ID: 32140600
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and a potential drugtarget of RARβ in non-small-cell lung carcinoma: a meta-analysis and a systematic review.
Song X; Shi K; Zhou SJ; Yu DP; Liu Z; Han Y
Drug Des Devel Ther; 2016; 10():1345-54. PubMed ID: 27103788
[TBL] [Abstract][Full Text] [Related]
5. Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines.
Sarne V; Huter S; Braunmueller S; Rakob L; Jacobi N; Kitzwögerer M; Wiesner C; Obrist P; Seeboeck R
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605217
[TBL] [Abstract][Full Text] [Related]
6. Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.
Kristiansen S; Nielsen D; Sölétormos G
Clin Epigenetics; 2016; 8():35. PubMed ID: 27042241
[TBL] [Abstract][Full Text] [Related]
7. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
Koudonas A; Papaioannou M; Kampantais S; Anastasiadis A; Hatzimouratidis K; Dimitriadis G
Medicine (Baltimore); 2022 Jul; 101(28):e29599. PubMed ID: 35838992
[TBL] [Abstract][Full Text] [Related]
8. Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events.
Keeley B; Stark A; Pisanic TR; Kwak R; Zhang Y; Wrangle J; Baylin S; Herman J; Ahuja N; Brock MV; Wang TH
Clin Chim Acta; 2013 Oct; 425():169-75. PubMed ID: 23911908
[TBL] [Abstract][Full Text] [Related]
9. Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective.
Munteanu R; Tomuleasa C; Iuga CA; Gulei D; Ciuleanu TE
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001653
[TBL] [Abstract][Full Text] [Related]
10. An Update on Potential Molecular Biomarkers of Dietary Phytochemicals Targeting Lung Cancer Interception and Prevention.
Peter RM; Chou PJ; Shannar A; Patel K; Pan Y; Dave PD; Xu J; Sarwar MS; Kong AT
Pharm Res; 2023 Nov; 40(11):2699-2714. PubMed ID: 37726406
[TBL] [Abstract][Full Text] [Related]
11. Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer.
Jie C; Li R; Cheng Y; Wang Z; Wu Q; Xie C
Front Immunol; 2023; 14():1122352. PubMed ID: 36875059
[TBL] [Abstract][Full Text] [Related]
12. DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicine.
Zhang G; Wang Z; Song P; Zhan X
EPMA J; 2022 Dec; 13(4):649-669. PubMed ID: 36505890
[TBL] [Abstract][Full Text] [Related]
13. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Guru SA; Sumi MP; Mir R; Beg MMA; Koner BC; Saxena A
BMC Cancer; 2022 Apr; 22(1):405. PubMed ID: 35421941
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylation in Lung Cancer: Mechanisms and Associations with Histological Subtypes, Molecular Alterations, and Major Epidemiological Factors.
Hoang PH; Landi MT
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205708
[TBL] [Abstract][Full Text] [Related]
15. The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer.
Cheng YY; Rath EM; Linton A; Yuen ML; Takahashi K; Lee K
Lung Cancer (Auckl); 2020; 11():1-11. PubMed ID: 32021524
[TBL] [Abstract][Full Text] [Related]
16. RASSF1A controls tissue stiffness and cancer stem-like cells in lung adenocarcinoma.
Pankova D; Jiang Y; Chatzifrangkeskou M; Vendrell I; Buzzelli J; Ryan A; Brown C; O'Neill E
EMBO J; 2019 Jul; 38(13):e100532. PubMed ID: 31268606
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of DAPK promoter methylation in non-small-cell lung cancer: a systematic review and meta-analysis.
Zhang Y; Wu J; Huang G; Xu S
Cancer Manag Res; 2018; 10():6897-6904. PubMed ID: 30588095
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of
Ma H; Chen X; Hu H; Li B; Ying X; Zhou C; Zhong J; Zhao G; Duan S
Oncol Lett; 2018 Jun; 15(6):9017-9024. PubMed ID: 29805634
[TBL] [Abstract][Full Text] [Related]
19. An epigenetic classifier for early stage lung cancer.
Su Y; Fang HB; Jiang F
Clin Epigenetics; 2018; 10():68. PubMed ID: 29796119
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas.
Kottorou AE; Antonacopoulou AG; Dimitrakopoulos FD; Diamantopoulou G; Sirinian C; Kalofonou M; Theodorakopoulos T; Oikonomou C; Katsakoulis EC; Koutras A; Makatsoris T; Demopoulos N; Stephanou G; Stavropoulos M; Thomopoulos KC; Kalofonos HP
Oncotarget; 2018 Apr; 9(30):21411-21428. PubMed ID: 29765549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
